CompletedNCT04781998
Liraglutide for weight-related health in forensic psychiatric care
About this title
Read the official source — NCT04781998Medication studyAges 18–65DenmarkMental health
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- RoskildeSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: July 1, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 24
- Sponsor
- Anders Fink-Jensen, MD, DMSci
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Denmark
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04781998
- Official title
Show the full official title
Is Pharmacological Treatment With the Glucagon-like Peptide-1 Receptor Agonist Liraglutide 3mg (Saxenda®) Once-daily a Viable Treatment for Weight Management in Forensic Psychiatry Patients? A Feasibility Study.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Roskilde
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Anders Fink-Jensen, MD, DMSci.
Did this study involve medication?
Yes. The study involved medication, including liraglutide 3 mg (Saxenda®) once-daily.
Who was this study for?
Listed age limits: 18 years to 65 years.
